Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. - sprookjes - yvandenbroek - TriplyDB

Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089.

Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089.

http://www.wikidata.org/entity/Q33228030

about

Duration of adjuvant chemotherapy for patients with non-metastatic colorectal cancer Clinical management of localized colon cancer with capecitabine Single Nucleotide Polymorphisms as Prognostic and Predictive Factors of Adjuvant Chemotherapy in Colorectal Cancer of Stages I and II The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 mont Optimizing adjuvant therapy and survivorship care of stage III colon cancer.Racial disparities in receipt and comparative effectiveness of oxaliplatin for stage III colon cancer in older adults Safety analysis of two different regimens of uracil-tegafur plus leucovorin as adjuvant chemotherapy for high-risk stage II and III colon cancer in a phase III trial comparing 6 with 18 months of treatment: JFMC33-0502 trial New frontiers in the treatment of colorectal cancer: Autophagy and the unfolded protein response as promising targets Change in clinical outcomes during the transition of adjuvant chemotherapy for stage III colorectal cancer.Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer.Mangafodipir a Selective Cytoprotectant - with Special Reference to Oxaliplatin and Its Association to Chemotherapy-Induced Peripheral Neuropathy (CIPN)Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer.Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01.Adjuvant chemoradiotherapy of advanced resectable rectal cancer: results of a randomised trial comparing modulation of 5-fluorouracil with folinic acid or with interferon-α.Adjuvant therapy for resected high-risk colon cancer: Current standards and controversies Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy.Personalized colon cancer care in 2010.Mature Results of a Prospective Randomized Trial Comparing 5-Flourouracil with Leucovorin to 5-Flourouracil with Levamisole as Adjuvant Therapy of Stage II and III Colorectal Cancer- The Israel Cooperative Oncology Group (ICOG) Study.Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401 Comparison of outcomes after fluorouracil-based adjuvant therapy for stages II and III colon cancer between 1978 to 1995 and 1996 to 2007: evidence of stage migration from the ACCENT database.Cancer stem cell gene profile as predictor of relapse in high risk stage II and stage III, radically resected colon cancer patients.Combination therapy in high-risk stage II or stage III colon cancer: current practice and future prospects.Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581 Challenges in the management of stage II colon cancer Stage III Colon Cancer: The Individualized Strategy of Adjuvant Chemotherapy for Aged Under and Over 70 Race and Insurance Differences in the Receipt of Adjuvant Chemotherapy Among Patients With Stage III Colon Cancer.Chemotherapy use in stage III colon cancer: a National Cancer Database analysis Feasibility of 5-days-on/2-days-off UFT/leucovorin in post-operative long-term adjuvant chemotherapy for colorectal cancer.Impact of adjuvant treatment modalities on survival outcomes in curatively resected pancreatic and periampullary adenocarcinoma.Adjuvant therapies for colorectal cancer.Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer.Effects of 5-fluorouracil adjuvant treatment of colon cancer.Association Between Time (Initiation and Length) and Oncological Outcomes for the Patients with Colon Cancer Treated with Adjuvant Chemotherapy Chemotherapy for colorectal cancer in the metastatic and adjuvant setting: past, present and future.Patterns of Colorectal Cancer Care in the United States: 1990-2010.Nodal staging score: a tool to assess adequate staging of node-negative colon cancer.Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials.Metastatic colorectal cancer-past, progress and future Adjuvant Therapy for Stage II and III Colon Cancer: Consensus Report of the International Society of Gastrointestinal Oncology.

P2860

Q24240635-F197555B-67A3-4BC5-A450-5FFDA0AC8DB6 Q24611758-437851FF-DA6C-42C5-8FF6-47A10DCB91E8 Q26765344-4952096C-D105-4DE0-A8F8-30DC31AE9681 Q28681140-2BD3FE6C-5D71-4E6C-90E5-EA43CE85A3C8 Q30249616-54CC3396-C902-45D6-99B4-9534A7AEDC4E Q30418988-AE09D1AA-B7F5-4D63-A188-C3B3904FC6B7 Q33656724-E3B3589C-F7A0-44C9-ACA2-C5F0F7821AE8 Q33731804-8AB84BAA-3467-4769-814C-2A67DCBEEEE5 Q33745767-0E64D4DE-9ED9-4019-8181-D455CDE69328 Q33840352-9A7D2DB9-1E5A-4C92-9F88-A006A60EE278 Q33868520-88733896-5D96-4865-9D4E-D7ADE8CDDB1F Q33946721-5E3B2195-7E74-4520-9186-C1222459DEAB Q34039871-E3B5EFB2-A5E7-4DFF-8261-7F04E3C4AF01 Q34255956-998848B2-515A-46DD-8B5E-00BE1D507777 Q34368278-20C3CFE0-131F-43F4-A1F8-6890E180905E Q34632080-A0DED81B-3989-41C4-8D49-75D405EAB544 Q34731381-B20F8776-B009-4238-ABEE-21432BB3456F Q34751755-EF421108-49D5-487B-BD9A-EBE509C21395 Q34879258-4502F06C-7967-477A-8849-EB9EF774F2DA Q34974760-5038A606-4C64-4CE5-96A4-B68422E2D550 Q34984086-BE47E674-01E7-4C6C-991A-40C442D92ABE Q35076279-ABAEDE34-6E9F-4E0A-BCEE-F2533F489405 Q35170266-539E4EA6-9064-428B-B90C-1C569C0E3331 Q35622839-C42F8EAC-39E0-43D3-B20F-97E411DE561D Q35780153-4A199210-265A-4E22-A967-73155B99DE21 Q35916635-AE2CCD5E-048A-4084-AEA3-7AC0D2A91EB4 Q35978879-DAE5B9E5-D85F-403A-B1E9-4DC2604F10CA Q35995117-CEC378E8-376C-47D6-9017-6E6F1D842ECA Q36029954-9D614CB8-F2F6-4ED9-A8C7-392CE6240A49 Q36177963-60C14840-E74C-4719-83FD-C56867B3D6D5 Q36300533-2BF5BC48-E02F-4337-966D-DBF471430325 Q36324953-5604FD05-1432-48EC-B216-158A4312C45C Q36499247-0CB23E86-55CE-4314-8592-D6D6557B117D Q36643640-B851EF1B-D8DF-4EBA-A0D5-BAA57E76F4CE Q36788478-5235C64A-201B-4D1B-B9CD-FC8F1396C721 Q36824126-F6583F82-18D6-410C-AF77-C301631076C9 Q36836069-BB7AB6BE-F637-40BE-9D31-E2DF400424CD Q36862977-84846C24-1EFE-4D09-9686-C1EF06583C98 Q36893806-C4AAE0BE-27F5-494C-87FC-3E1C4C5526CA Q37076532-51A8938F-8ABC-4DE1-AE10-1048E42E424F

P2860

Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089.

http://www.wikidata.org/entity/Q33228030

description

2005 nî lūn-bûn

@nan

2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Phase III study of fluorouraci ...... nal report of Intergroup 0089.

@ast

Phase III study of fluorouraci ...... nal report of Intergroup 0089.

@en

type

label

Phase III study of fluorouraci ...... nal report of Intergroup 0089.

@ast

Phase III study of fluorouraci ...... nal report of Intergroup 0089.

@en

prefLabel

Phase III study of fluorouraci ...... nal report of Intergroup 0089.

@ast

Phase III study of fluorouraci ...... nal report of Intergroup 0089.

@en

P1433

Q33228030-670E925E-AF26-4ED3-84D1-02E07134AC66

P1476

Q33228030-A0ED2F1F-2D0B-4E43-8FCD-CA23A2674411

P2093

Q33228030-40E182B3-ED51-49C5-A105-74818939A096

Q33228030-567A7DB1-6146-485A-A19E-CF5F60647320

Q33228030-634792DA-7E6E-41D2-892D-D36C7880481A

Q33228030-6A24AF73-3222-43D4-A2F0-793EEB485D57

Q33228030-8C4B6245-3B02-48EF-87C0-8146661906D4

Q33228030-C1D6504A-8CD9-4A36-838C-E6E37DFF6DF5

Q33228030-C512F86C-620D-4F00-8888-58A8FDCFED05

P304

Q33228030-D7A1EF6E-2F19-4F36-BBBA-4361E4CACF83

P31

Q33228030-443FFC59-EC1B-4C3A-8FEC-8690FECEBAA0

P356

Q33228030-73D3E90F-5DEE-4C55-901E-7F0DE7D53DF8

P407

Q33228030-4F3B5065-24E4-4424-B4BC-F8A06F711AC9

P433

Q33228030-3BE6BE6E-4E11-4690-A98A-202559C98258

P478

Q33228030-E68E7C7B-2103-4813-B454-E280AB36F5FC

P577

Q33228030-BB143A6B-C1DD-4119-B3E9-731444B1CEF0

P698

Q33228030-055155D5-E662-471A-9F7D-B6E1A8EC7936

P356

JCO.2004.00.5686

P1433

Journal of Clinical Oncology

P1476

Phase III study of fluorouraci ...... nal report of Intergroup 0089.

@en

P2093

Daniel G Haller

http://www.w3.org/2001/XMLSchema#string

Don V Jackson

http://www.w3.org/2001/XMLSchema#string

John S Macdonald

http://www.w3.org/2001/XMLSchema#string

Mark A O'Rourke

http://www.w3.org/2001/XMLSchema#string

Michael S Frontiera

http://www.w3.org/2001/XMLSchema#string

Paul J Catalano

http://www.w3.org/2001/XMLSchema#string

Robert J Mayer

http://www.w3.org/2001/XMLSchema#string

P304

8671-8678

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2004.00.5686

http://www.w3.org/2001/XMLSchema#string

P407

P433

34

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P577

2005-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16314627

http://www.w3.org/2001/XMLSchema#string